Ask HopeStage to review this study with me
Study ID: NCT01431092. We help you review the study, but cannot decide medical eligibility.
CompletedNCT01431092
Prolonged-release Melatonin Versus Placebo for Benzodiazepine Discontinuation in people with Schizophrenia: a study
This study is completed in Denmark. It focuses on schizophrenia.
Schizophrenia, BipolarityDrugOver 18 Years
Key information made simple
What is this study testing?
This study is testing whether a study medication may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive a study medication, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Denmark.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
The official record suggests in-person participation through a university, with sites including Center for Neuropsychiatric Schizophrenia Research (CNSR)/Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), University of Copenhagen, Mental Health Centre Glostrup, Mental Health Services - Capital Region of Denmark in Glostrup Municipality. Participation appears to involve guided sessions or support activities with check-ins on how they fit into daily life. The main fit is usually matching the main diagnosis and being able to understand the study and consent, while common reasons not to take part include pregnancy or breastfeeding and other factors that could make participation unsuitable. This is a later-stage study, which usually means the approach is being followed in broader real-world use.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateOctober 2011
- Recruitment status
- Completed
- Estimated enrollment
- Not clearly listed
- Sponsor
- Lone Baandrup
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- Denmark
- Age range
- Over 18 Years
- Official registry ID
- NCT01431092
- Official title
- Prolonged-release Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia: a Randomized Clinical Trial
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT01431092. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in Denmark.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.
Who might this study be for?
This study may concern people with schizophrenia; age range: Over 18 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
Will I need to change, stop, or stabilize my current treatment?
The public registry appears to mention rules about current treatment, stability, stopping treatment, or dose changes. Do not change your treatment for a study without medical guidance. Ask the study team and your clinician what is required, what is not allowed, and how safety is monitored.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Lone Baandrup, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is completed. It may still be useful for understanding the research, but you are unlikely to be able to join.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT00216476
Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in schizophrenia
This study is completed in France, in the United Kingdom, in Austria, .... It is testing Long-acting Injectable Risperidone and Quetiapine Tablets for schizophrenia.
CompletedNCT02713282
Transition to the Paliperidone Palmitate 3-Month Formulation for schizophrenia
This study is completed in France, in the United Kingdom, in Croatia, .... It is testing Transition to the Paliperidone Palmitate 3-Month Formulation for schizophrenia.
CompletedNCT01926912
Usage of Paliperidone Palmitate in people with Schizophrenia in a Hospital Setting
This study is completed in Belgium, in Bulgaria, in Denmark, .... It is testing usage of Paliperidone Palmitate for schizophrenia.